These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35430138)

  • 1. Prediction of recurrence of non-muscle invasive bladder cancer: The role of androgen receptor and miRNA-2909.
    Muzaail HH; El-Assmy A; Harraz AM; Awadalla A; Shokeir AA; Abdel-Aziz AF
    Urol Oncol; 2022 May; 40(5):197.e25-197.e35. PubMed ID: 35430138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y
    BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder.
    Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S
    Pathol Oncol Res; 2019 Jul; 25(3):987-994. PubMed ID: 29862474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.
    Sikic D; Breyer J; Hartmann A; Burger M; Erben P; Denzinger S; Eckstein M; Stöhr R; Wach S; Wullich B; Keck B; Wirtz RM; Otto W
    Transl Oncol; 2017 Jun; 10(3):340-345. PubMed ID: 28342317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
    Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
    Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence.
    Izumi K; Ito Y; Miyamoto H; Miyoshi Y; Ota J; Moriyama M; Murai T; Hayashi H; Inayama Y; Ohashi K; Yao M; Uemura H
    Oncotarget; 2016 Mar; 7(12):14153-60. PubMed ID: 26885620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
    Spagnuolo M; Costantini M; Ferriero M; Varmi M; Sperduti I; Regazzo G; Cicchillitti L; Díaz Méndez AB; Cigliana G; Pompeo V; Russo A; Laquintana V; Mastroianni R; Piaggio G; Anceschi U; Brassetti A; Bove A; Tuderti G; Flammia RS; Gallucci M; Simone G; Rizzo MG
    J Exp Clin Cancer Res; 2020 Apr; 39(1):68. PubMed ID: 32303246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Sanguedolce F; Cormio L; Carrieri G; Calò B; Russo D; Menin A; Pastore AL; Greco F; Bozzini G; Galfano A; Pini G; Porreca A; Mugavero F; Falsaperla M; Ceruti C; Cindolo L; Antonelli A; Minervini A
    Histol Histopathol; 2020 May; 35(5):423-432. PubMed ID: 31803932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
    Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
    Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
    Lin YL; Wang YL; Ma JG; Li WP
    J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
    Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
    Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
    Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
    Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.